164 related articles for article (PubMed ID: 16439677)
1. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).
Secchiero P; Barbarotto E; Tiribelli M; Zerbinati C; di Iasio MG; Gonelli A; Cavazzini F; Campioni D; Fanin R; Cuneo A; Zauli G
Blood; 2006 May; 107(10):4122-9. PubMed ID: 16439677
[TBL] [Abstract][Full Text] [Related]
2. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
[TBL] [Abstract][Full Text] [Related]
3. Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity.
Zauli G; di Iasio MG; Secchiero P; Dal Bo M; Marconi D; Bomben R; Del Poeta G; Gattei V
Curr Cancer Drug Targets; 2009 Jun; 9(4):510-8. PubMed ID: 19519319
[TBL] [Abstract][Full Text] [Related]
4. The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells.
Secchiero P; Voltan R; di Iasio MG; Melloni E; Tiribelli M; Zauli G
Clin Cancer Res; 2010 Mar; 16(6):1824-33. PubMed ID: 20215548
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
Zauli G; Voltan R; Bosco R; Melloni E; Marmiroli S; Rigolin GM; Cuneo A; Secchiero P
Clin Cancer Res; 2011 Feb; 17(4):762-70. PubMed ID: 21106726
[TBL] [Abstract][Full Text] [Related]
6. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.
Coll-Mulet L; Iglesias-Serret D; Santidrián AF; Cosialls AM; de Frias M; Castaño E; Campàs C; Barragán M; de Sevilla AF; Domingo A; Vassilev LT; Pons G; Gil J
Blood; 2006 May; 107(10):4109-14. PubMed ID: 16439685
[TBL] [Abstract][Full Text] [Related]
7. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G
Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157
[TBL] [Abstract][Full Text] [Related]
8. Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3.
Voltan R; Secchiero P; Corallini F; Zauli G
Mol Carcinog; 2014 Jun; 53(6):498-504. PubMed ID: 23192887
[TBL] [Abstract][Full Text] [Related]
9. Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.
Wang DM; Liu L; Fan L; Zou ZJ; Zhang LN; Yang S; Li JY; Xu W
Cancer Biol Ther; 2012 Dec; 13(14):1522-8. PubMed ID: 23052131
[TBL] [Abstract][Full Text] [Related]
10. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G
Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
Barbarotto E; Corallini F; Rimondi E; Fadda R; Mischiati C; Grill V; Vaccarezza M; Celeghini C
J Cell Biochem; 2008 May; 104(2):595-605. PubMed ID: 18092340
[TBL] [Abstract][Full Text] [Related]
12. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.
Secchiero P; Melloni E; di Iasio MG; Tiribelli M; Rimondi E; Corallini F; Gattei V; Zauli G
Blood; 2009 Apr; 113(18):4300-8. PubMed ID: 19190243
[TBL] [Abstract][Full Text] [Related]
13. Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3.
Agnoletto C; Melloni E; Casciano F; Rigolin GM; Rimondi E; Celeghini C; Brunelli L; Cuneo A; Secchiero P; Zauli G
Oncotarget; 2014 Jun; 5(12):4347-60. PubMed ID: 24962518
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.
Voltan R; Rimondi E; Melloni E; Rigolin GM; Casciano F; Arcidiacono MV; Celeghini C; Cuneo A; Zauli G; Secchiero P
Oncotarget; 2016 Oct; 7(43):70623-70638. PubMed ID: 27661115
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells.
Secchiero P; Melloni E; Tiribelli M; Gonelli A; Zauli G
J Leukoc Biol; 2008 Feb; 83(2):434-7. PubMed ID: 17998303
[TBL] [Abstract][Full Text] [Related]
16. SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155.
di Iasio MG; Norcio A; Melloni E; Zauli G
Invest New Drugs; 2012 Dec; 30(6):2403-6. PubMed ID: 22238073
[TBL] [Abstract][Full Text] [Related]
17. S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.
Liu L; Fan L; Fang C; Zou ZJ; Yang S; Zhang LN; Li JY; Xu W
Cancer Sci; 2012 Dec; 103(12):2056-63. PubMed ID: 22937789
[TBL] [Abstract][Full Text] [Related]
18. Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.
Pozzo F; Dal Bo M; Peragine N; Bomben R; Zucchetto A; Rossi F; Degan M; Rossi D; Chiarenza A; Grossi A; Di Raimondo F; Zaja F; Pozzato G; Secchiero P; Gaidano G; Del Poeta G; Zauli G; Fo À R; Guarini A; Gattei V
J Hematol Oncol; 2013 Nov; 6():83. PubMed ID: 24283248
[TBL] [Abstract][Full Text] [Related]
19. Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.
Ciardullo C; Aptullahoglu E; Woodhouse L; Lin WY; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
Haematologica; 2019 Dec; 104(12):2429-2442. PubMed ID: 31004033
[TBL] [Abstract][Full Text] [Related]
20. Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells.
Tseng HY; Jiang CC; Croft A; Tay KH; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
Mol Cancer Ther; 2010 Dec; 9(12):3363-74. PubMed ID: 21159614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
